Qiagen
-
Standardized solutions for molecular analysis of FFPE samples
Qiagen has launched several products that assist in the molecular analysis of formalin-fixed, paraffin-embedded (FFPE) tissue samples. The offering provides scientists with a range of dedicated kits over the whole FFPE workflow, from the isolati…
Qiagen | 21 November 2010
-
CE- IVD marked tests for cancer companion diagnostics
Qiagen is launching several tests for cancer companion diagnostics, CE-marked with the Rotor-Gene Q thermocycler (EGFR) and the PyroMark pyrosequencing system (EGFR, NRAS, KRAS, BRAF). The new tests are used in personalized healthcare of cancer …
Qiagen | 28 October 2010
-
Qiagen Acquires License for Key PI3K Gene
Qiagen has announced that its wholly owned subsidiary DxS has acquired the global and exclusive license for biomarker PI3K from Johns Hopkins University, to develop real-time Polymerase Chain Reaction (RT-PCR) and endpoint PCR assays. Research has sh…
Qiagen | 26 February 2010
-
Qiagen and Pfizer to Develop Diagnostic for Brain Tumor Vaccine
Pfizer and DxS (a wholly owned subsidiary of Qiagen) have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110) – an immunotherapy vaccine in development for the treatment of Glioblastoma Multiforme (GBM). F…
Qiagen | 18 February 2010
-
Qiagen and WuXi AppTec Partner for Biomarker Development in China
Qiagen Asia Pacific and WuXi AppTec have announced a partnership to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases. The former will provid…
Qiagen | 13 January 2010
-
Qiagen to Acquire SABiosciences
Qiagen has signed an agreement to acquire SABiosciences Corporation, a privately-held developer and manufacturer of disease- and pathway-focused Polymerase Chain Reaction (PCR) assay panels. The transaction is valued at US$90 million in cash (subject…
Qiagen | 27 November 2009
-
Qiagen Acquires DxS
Qiagen has acquired DxS, a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, UK. The transaction is valued at approximately US$95 million in cash, plus up to an additional US$35 million if specifi…
Qiagen | 09 October 2009
-
Qiagen Acquires PCR licenses from Roche and Idaho Technology
Qiagen has acquired additional licenses from Roche and Idaho Technology that are related to the use of instrumentation and reagents for PCR-based molecular testing. Financial details were not disclosed. The agreements cover thermal cycler rights …
Qiagen | 25 September 2009
-
Qiagen Launches Product to Replace Invasive Procedures
Qiagen has announced the launch of a product for the extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. The QIAamp Circulating Nucleic Acid Kit is expected to facilita…
Qiagen | 09 June 2009
-
Qiagen: Cervical Cancer Screening
Qiagen and the Chittaranjan National Cancer Institute (CNCI) have announced a collaboration to establish a cervical cancer screening program for women in Kolkata, India. The former will provide its diagnostic tests for the human papillomavirus (HPV).…
Qiagen | 05 May 2009
